sgb 1534 has been researched along with apraclonidine in 2 studies
| Studies (sgb 1534) | Trials (sgb 1534) | Recent Studies (post-2010) (sgb 1534) | Studies (apraclonidine) | Trials (apraclonidine) | Recent Studies (post-2010) (apraclonidine) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 427 | 98 | 56 |
| Protein | Taxonomy | sgb 1534 (IC50) | apraclonidine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.004 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.004 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagatomo, T; Tsuchihashi, H | 1 |
| Aono, J; Nagatomo, T; Nakamura, T; Tajiri, A; Tsuchihashi, H | 1 |
2 other study(ies) available for sgb 1534 and apraclonidine
| Article | Year |
|---|---|
Alpha-blocking potencies of antihypertensive agents (prazosin, terazosin, bunazosin, SGB-1534 and ketanserin) having with quinazoline or quinazolinedione as assessed by radioligand binding assay methods in rat brain.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Brain; Cell Membrane; Clonidine; Dihydroalprenolol; Ketanserin; Male; Prazosin; Quinazolines; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1989 |
Effect of 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)- quinazolinedione monophydrochloride (SGB-1534), an antihypertensive agent, on 3H-prazosin and 3H-p-aminoclonidine binding to alpha 1- and alpha 2-adrenoceptors in dog brain and aorta.
Topics: Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Brain; Clonidine; Dogs; Female; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Prazosin; Quinazolines; Receptors, Adrenergic, alpha | 1988 |